Zealand Pharma A/S (ZEAL) Stock Analysis

Zealand Pharma A/S (ZEAL) Healthcare & Pipeline Overview

Zealand Pharma A/S is a Danish biotechnology company specializing in the discovery, development, and commercialization of peptide-based medicines, particularly for gastrointestinal and metabolic disorders, positioning itself in a competitive landscape with a focus on addressing unmet medical needs through innovative therapies like Dasiglucagon and glepaglutide.

What Is the Investment Thesis for ZEAL?

Zealand Pharma presents a compelling investment thesis based on its focus on peptide-based therapeutics addressing significant unmet needs in gastrointestinal and metabolic diseases. The company's marketed products, including Adlyxin and Lyxumia, provide a revenue base, while Dasiglucagon and glepaglutide represent key growth drivers with potential for significant market penetration upon successful completion of Phase III trials and regulatory approval. The P/E ratio of 3.26, coupled with a high profit margin of 70.0% and a gross margin of 99.8%, indicates strong profitability. Upcoming catalysts include the potential approval of Dasiglucagon for congenital hyperinsulinism. Potential risks include clinical trial failures and competition from established pharmaceutical companies.

Based on FMP financials and quantitative analysis

ZEAL Key Highlights

P/E ratio of 3.26, indicating a potentially undervalued stock relative to earnings.

• Profit Margin of 70.0%, showcasing strong profitability and efficient operations.
• Gross Margin of 99.8%, reflecting the company's ability to maintain high revenue relative to the cost of goods sold.
• Beta of 1.34, suggesting that the stock is more volatile than the overall market.
• No dividend yield, indicating that the company is reinvesting its earnings for growth.

Who Are ZEAL's Competitors?

ZEAL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ZEAL's Key Strengths?

Strong pipeline of peptide-based therapeutics.

• Established partnerships with major pharmaceutical companies.
• High profit and gross margins.
• Proprietary drug discovery platform.

What Are ZEAL's Weaknesses?

Reliance on a limited number of products.

• High research and development costs.
• Dependence on regulatory approvals.
• Competition from larger pharmaceutical companies.

What Could Drive ZEAL Stock Higher?

Potential FDA approval of Dasiglucagon for congenital hyperinsulinism.

• Phase III clinical trial results for glepaglutide in short bowel syndrome.
• Continued commercialization and market penetration of Adlyxin and Lyxumia.
• Development and advancement of the Dasiglucagon dual-hormone artificial pancreas.

What Are the Key Risks for ZEAL?

Clinical trial failures for Dasiglucagon or glepaglutide.

• Regulatory delays or rejection of drug approvals.
• Competition from established pharmaceutical companies in the diabetes and gastrointestinal markets.
• Currency exchange rate fluctuations impacting ADR value.
• Intellectual property challenges or patent expirations.

What Are the Growth Opportunities for ZEAL?

• Dasiglucagon for Congenital Hyperinsulinism: Dasiglucagon is currently in Phase III clinical trials for the treatment of congenital hyperinsulinism (CHI). CHI is a rare genetic disorder that causes the pancreas to produce too much insulin, leading to frequent and severe hypoglycemia. If approved, Dasiglucagon could become the first and only ready-to-use glucagon analog specifically indicated for CHI, addressing a significant unmet medical need in a market with limited treatment options. The global market for CHI treatments is estimated to reach $500 million by 2030, presenting a substantial revenue opportunity for Zealand Pharma.
• Glepaglutide for Short Bowel Syndrome: Glepaglutide, a long-acting GLP-2 analog, is in Phase III clinical trials for the treatment of short bowel syndrome (SBS). SBS is a condition that occurs when the small intestine is unable to absorb enough nutrients and fluids from food. Glepaglutide has the potential to improve intestinal absorption and reduce the need for parenteral support in SBS patients. The market for SBS treatments is projected to reach $2 billion by 2028, offering a significant growth opportunity for Zealand Pharma.
• Dasiglucagon Dual-Hormone Artificial Pancreas: Zealand Pharma is developing a Dasiglucagon dual-hormone artificial pancreas for automated diabetes management in collaboration with Beta Bionics, Inc. This system combines a continuous glucose monitor, an insulin pump, and a Dasiglucagon pump to automatically regulate blood glucose levels. The artificial pancreas market is expected to grow to $1.5 billion by 2027, driven by the increasing prevalence of diabetes and the demand for more convenient and effective diabetes management solutions.
• Expansion into New Therapeutic Areas: Zealand Pharma has the potential to leverage its expertise in peptide-based drug discovery and development to expand into new therapeutic areas beyond gastrointestinal and metabolic diseases. The company could explore opportunities in areas such as obesity, cardiovascular disease, and inflammatory disorders, which represent large and growing markets with significant unmet medical needs. This diversification strategy could reduce the company's reliance on its existing pipeline and create new revenue streams.
• Strategic Partnerships and Collaborations: Zealand Pharma can continue to pursue strategic partnerships and collaborations with other pharmaceutical and biotechnology companies to accelerate the development and commercialization of its products. Collaborations can provide access to new technologies, funding, and market expertise, allowing Zealand Pharma to expand its reach and maximize the value of its pipeline. The company's existing partnerships with Sanofi, Boehringer Ingelheim, Alexion Pharmaceuticals, and Beta Bionics demonstrate its ability to successfully collaborate with leading industry players.

What Threats Does ZEAL Face?

• Clinical trial failures.
• Regulatory setbacks.
• Competition from generic drugs.
• Changes in healthcare policies.

What Are ZEAL's Competitive Advantages?

• Proprietary peptide-based drug discovery platform.
• Strong intellectual property protection for its drug candidates.
• Established partnerships with major pharmaceutical companies.
• Specialized expertise in gastrointestinal and metabolic diseases.

What Does ZEAL Do?

Zealand Pharma A/S, founded in 1998 and headquartered in Copenhagen, Denmark, is a biotechnology company dedicated to the discovery, development, and commercialization of innovative peptide-based medicines. The company focuses on addressing unmet medical needs within gastrointestinal and metabolic diseases, as well as other specialty disease areas. Zealand Pharma markets lixisenatide under the brand names Adlyxin and Lyxumia, used in the treatment of type 2 diabetes. Additionally, the company offers Dasiglucagon, a ready-to-use glucagon analog designed for the treatment of severe hypoglycemia. Dasiglucagon is available in a single-use syringe or autoinjector and is also being developed for congenital hyperinsulinism and post-bariatric surgery hypoglycemia. Furthermore, Zealand Pharma is developing a Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes glepaglutide, a long-acting GLP-2 analog currently in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma has established collaboration agreements with companies such as Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc., to further expand its research and development efforts and commercial reach.

What Products and Services Does ZEAL Offer?

• Discovers novel peptide-based medicines.
• Develops peptide therapeutics for gastrointestinal and metabolic diseases.
• Commercializes drugs like Adlyxin and Lyxumia for type 2 diabetes.
• Markets Dasiglucagon for severe hypoglycemia.
• Develops Dasiglucagon for congenital hyperinsulinism and post-bariatric surgery hypoglycemia.
• Creates dual-hormone artificial pancreas systems for automated diabetes management.
• Advances glepaglutide for short bowel syndrome treatment.

How Does ZEAL Make Money?

• Develops and patents novel peptide-based drug candidates.
• Out-licenses or co-develops drug candidates with larger pharmaceutical companies.
• Generates revenue through product sales of approved drugs like Adlyxin and Lyxumia.
• Receives milestone payments and royalties from partnered programs.

What Industry Does ZEAL Operate In?

Zealand Pharma operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and significant growth potential. The market for peptide-based therapeutics is expanding, driven by the increasing prevalence of metabolic and gastrointestinal disorders. Zealand Pharma competes with other biotechnology and pharmaceutical companies, including ALBO, ATRI, CDMO, CMRX and GRCL, focusing on similar therapeutic areas. The company's success depends on its ability to innovate, secure regulatory approvals, and effectively commercialize its products.

Who Are ZEAL's Key Customers?

• Patients with type 2 diabetes using Adlyxin and Lyxumia.
• Individuals experiencing severe hypoglycemia requiring Dasiglucagon.
• Patients with congenital hyperinsulinism who may benefit from Dasiglucagon.
• Individuals with short bowel syndrome potentially treated with glepaglutide.

Company Profile

Zealand Pharma A/S operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Copenhagen, DK. The company is led by CEO Emmanuel Dulac PharmD, MBA. ZEAL has traded publicly since 2017.

Return on equity for Zealand Pharma A/S stands at 42.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 41.8%, showing how much profit it generates from its asset base. ZEAL trades at a trailing price-to-earnings ratio of 3.10, below the Healthcare sector average of ~23x. Its free cash flow yield is 31.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 37.17 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 32.2%, the inverse of the P/E and a quick read on earnings relative to price.

ZEAL Financials

ZEAL Latest News

No recent news available for ZEAL.

Common Questions About ZEAL (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources